The combination therapy of atezolizumab, an anti-PDL1 antibody, and bevacizumab, a VEGF-neutralizing antibody, is becoming the frontline treatment for HCC [27, 28]. This evidence concerns the gene CD274 and hepatocellular carcinoma.